Journal
CURRENT MOLECULAR PHARMACOLOGY
Volume 9, Issue 4, Pages 289-299Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1874467208666150928153758
Keywords
Bone defects; clinical transition; differentiation; immunomodulation; mesenchymal stem cells; secretome
Funding
- Ministry of Science and Technology of PR China [2011AA020100]
- National Natural Science Foundation of China [30830052]
- National Key Scientific Program of China [2011CB964901]
- Program for Cheung Kong Scholars and Innovative Research Team in University-PCSIRT [IRT0909]
Ask authors/readers for more resources
Mesenchymal stem cells (MSCs) represent a new therapeutic paradigm for a number of diseases because they possess unique biological characteristics such as multipotency, immunomodulation and production of cytokines. Currently, 425 MSC based clinical trials have been conducted for at least 12 kinds of pathological conditions, with many completed trials demonstrating the safety and efficacy of MSCs. Here, we provide an overview of the clinical status of MSCs by searching the public clinical trials database http://clinicaltrials.gov. Particularly, the role of MSCs in clinical trials to treat bone defects and injuries is highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
